NightHawk Biosciences Inc

-0.02 (-4.35%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)13.72M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.12 Million
Adjusted EPS-$0.19
See more estimates
10-Day MA$0.59
50-Day MA$0.64
200-Day MA$0.80
See more pivots

NightHawk Biosciences Inc Stock, ASE:NHWK

627 Davis Drive, Suite 300, Morrisville, North Carolina 27560
United States of America
Phone: +1.919.240.7133
Number of Employees: 77


NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.